Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
Eitan Kerem, Michael W. Konstan(Rainbow Babies & Children's Hospital), K. De Boeck, Frank J. Accurso(Boston Children's Hospital), Isabelle Sermet‐Gaudelus, Michael Wilschanski, J.S. Elborn(Queen's University Belfast), Paola Melotti(Azienda Ospedaliera Universitaria Integrata Verona), Inez Bronsveld(University Medical Center Utrecht), Isabelle Fajac(Délégation Paris 5), Anne Malfroot(Vrije Universiteit Brussel), Daniel Rosenbluth, Patricia Walker(Mount Sinai Hospital), Susanna A. McColley(Lurie Children's Hospital), Christiane Knoop(Erasmus Hospital), Serena Quattrucci(Policlinico Umberto I), Ernst Rietschel(University of Cologne), Pamela L. Zeitlin(Johns Hopkins University), Jay Barth(PTC Therapeutics (United States)), Gary Elfring(PTC Therapeutics (United States)), Ellen Welch(PTC Therapeutics (United States)), Arthur Branstrom(PTC Therapeutics (United States)), Robert J. Spiegel(PTC Therapeutics (United States)), Stuart W. Peltz(PTC Therapeutics (United States)), Temitayo Ajayi(PTC Therapeutics (United States)), Steven M. Rowe(University of Alabama at Birmingham)
Cited by 335Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis